COMPANION DIAGNOSTICS

 

 

Drugs developed and prescribed to those that need them. Companion diagnostics herald a new era in personalised medicine that will decrease trial costs and accelerate the delivery of effective cures to patients. Additionally, health systems will experience a reduced expenditure and improved patient experience.

THIS YEAR’S WORLD LEADING COMPANION DIAGNOSTICS SPEAKERS

 

 

 

Companion Diagnostics, Tuesday 2 November 2021

08:40

Opening Remarks

Trevor Howe
09:00

Looking at the bigger picture: How do we make sure that we have the full picture with big data experiments

Joachim Reischl
09:20

Deep Medicine – towards the next generation of software-based precision medicine diagnostics

  • Evolution of precision medicine
  • AI in predicting clinical outcome
  • Software as Medical Device as Companion Diagnostic
Panel discussion
09:40

Essential Tools for Accelerating Pipeline Productivity & Success

What tools are in your toolkit? Join this leading biopharma panel discussion to find out how to give your AI-based drug discovery and development program a competitive edge and increase program success.
10:40

Networking Break

13:20

Networking Lunch Break

16:20

Networking Break

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 27/Jul/21 14:25

Companion Diagnostics, Wednesday 3 November 2021

Steffen Roellinger
09:00

Decentralised Clinical Trials

  • Discussing the adoption of decentralised clinical trials at Bayer
  • New digital addoption
  • The Bayer trials transformaiton over COVID-19
Andrew Kasarskis
09:00

Digital transformation over COVID-19 – Challenges for the future and perpetuating the efforts

  • COVID-19 lead to digital innovation by necessity, including telehealth, new apps and digital technologies, and data fusion and sharing advances.
  • Large opportunities exist to do much better with learning from data, however.This requires the following operational and cultural change:
-Proactive collection and use of coherent data sets as a baseline for public health and the infrastructure development to support that work.-Recommitment to evidence-based medicine and timely, rigorous assessment of clinical utility through ongoing clinical research with well-powered studies of strong statistical design coupled to careful monitoring of large observational data.
Said Ismail
09:20

Qatar Genome; Big data from an underrepresented region

  • Overview of the Qatar Genome Project (QGP)
  • Contributions to Middle East Genomics
  • QGP role COVID-19 research
  • Strategy for precision medicine implementation
09:20

SevenBridges

Panel discussion
09:40

BC Platforms - Keynote Panel

Paul Agapow
09:40

How to be right: effective use of clinical models and machine learning in the clinic

    There is an increasing demand for a sophisticated model to predict patient outcomes and suggest treatmentsUnfortunately, most proposed clinical models are not fit for purpose, being biased, unvalidated, or irrelevantHere we suggest best practices for the development and deployment of complex ML algorithms, resulting in more successful and effective models
10:20

Networking Break + Speed Networking

Dominik Hartl
Companion Diagnostics
11:20

Non-Oncology-Based Companion Diagnostics

Companion Diagnostics
11:40

Agilent

Companion Diagnostics
12:20

VIDENCE Reserved

13:00

Networking Lunch Break

Panel discussion
Companion Diagnostics
14:00

Assessing the value of sequencing as a standard in clinical trials

  • Should sequencing trial cohorts become a standard in clinical trials?
  • Case studies demonstrating value
  • Saving trails and gaining new insights through genomic data
  • Other metadata that should be included as a standard
Companion Diagnostics
14:40

OncoDNA Reserved

Sandra Smieszek
Companion Diagnostics
15:00

Viral genomics and clinical trials

Companion Diagnostics
15:20

Sponsor

John Castle
Companion Diagnostics
15:40

Molecular Glue Degraders: From Serendipity to Rational Design

Monte Rosa’s QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform enables us to rationally discover molecular glue degraders (MGDs). QuEEN comprises:
  • Degron encyclopedia: A growing catalogue of over 1500 proteins identified through our AI-driven approach, containing proteins of diverse protein classes across therapeutic areas, including highly credentialed targets previously deemed undruggable.
  • Proprietary MGD library: A diverse and continuously growing chemical library of drug-like MGDs that are rationally designed based on our expertise in molecular glue anatomy
  • Glueomics toolbox: A tailored suite of biochemical, structural biology, cellular, proteomics and in silico screening tools that connect degrons to MGDs
Leveraging QuEEN, we have identified and validated MGDs to highly validated and therapeutically relevant but undruggable proteins.
16:00

Networking Break

Jens K Habermann
Companion Diagnostics
16:40

BBMRI infrastructure supporting high quality samples and liquid biopsy translational research

18:00

Drinks Reception

last published: 27/Jul/21 14:25

Companion Diagnostics, Thursday 4 November 2021

Scott Chandler
09:00

Genetic Drivers of Response to Immunotherapy: Going Beyond the Tumor

09:20

GenomeSys

Thomas Hach
10:40

The Future of Precision Healthcare – Multi-Omics Humanized

  • Personalization of healthcare, not only of drug treatment, is the future
  • Patient influence, patient data and patient-desired outcomes are the most disruptive factors
  • How can we move from sterile biosignatures to a humanized approach?
last published: 27/Jul/21 14:26

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034